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Title 
Dressings and securements for the prevention of peripheral intravenous catheter failure (SAVE 
Trial) in adults: a pragmatic, randomised, controlled, superiority trial. 
 
ABSTRACT (300 words) 
Background: Two billion peripheral intravenous catheters (PIVCs) are used globally each 
year, but optimal dressing and securement methods are not well established. We compared the 
effectiveness and costs of three alternative approaches to standard non-bordered polyurethane 
dressings.  
Methods: Pragmatic, open, parallel, superiority, randomised controlled trial in two hospitals. 
Adults (≥18 years) with PIVCs of expected use >24 hours were randomly assigned (1:1:1:1) to 
(i) Tissue Adhesive with Polyurethane dressing, (ii) Bordered Polyurethane dressing, (iii) 
Securement Device with Polyurethane dressing, or (iv) Polyurethane dressing (controls). 
Randomisation was centralised, computer-generated, stratified, with concealed allocation. The 
primary outcome was PIVC failure (composite of dislodgement, occlusion, phlebitis, primary 
bloodstream, local infection). Participants and clinicians were not masked but infections were 
blind-adjudicated. Analysis was intention to treat. Trial registration: ACTRN12611000769987. 
Findings: Of 1807 randomised patients, 1697 (94%) had the primary endpoint available. PIVC 
failure was: 163/427 (38%) Tissue Adhesive with Polyurethane (absolute risk difference 
[ARD] -4∙5%, 95% CI -11∙1–2∙1%, p=0∙19); 169/423 (40%) Bordered Polyurethane (ARD -
2∙7%, 95% CI -9∙3%–3∙9%, p=0∙44); 176/425 (41%) Securement Device with Polyurethane 
(ARD -1∙2%, 95% CI -7∙9%–5∙4%, p=0∙73); and 180/422 (43%) Polyurethane controls. 
Between-group secondary outcomes were not significantly different for PIVC dwell, product 
durability, skin/PIVC colonisation, or PIVC failure type, except occlusion was less frequent 
for Tissue Adhesive with Polyurethane, than Polyurethane alone (16% vs 22%, Hazard Ratio 
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[HR] 0∙89, 95% CI 0∙80–0∙99, p=0∙027). There were three primary bloodstream infections 
(0.18%), of which one was PIVC-related, and 2% of participants had adverse skin reactions. 
Total costs were not significantly different between groups, but excluding infection costs, non-
bordered Polyurethane was least costly. Overall, 66% PIVCs required dressing reinforcement. 
Interpretation: Current dressing and securement methods are commonly associated with 
PIVC failure, adverse events, and poor durability. Cost is currently the major factor to consider 
in choice of products. 
 
Funding: Australian National Health and Medical Research Council (APP1041910). 
 
Keywords (MeSH): Vascular Access Devices; Occlusive Dressings; Catheterisation, 
Peripheral; Catheter-Related Infections; Infection Control; Randomised Controlled Trial 
 
Panel: Research in context (515 words) 
Evidence before this study 
We searched Medline, CINAHL, Cochrane Collaboration databases, and clinical trials 
registries for randomised controlled trials (RCTs) comparing any methods of dressing and 
securement method for peripheral intravenous catheters (PIVCs). Our search terms were 
“peripheral”, “intravenous”, “catheter/device/cannula”, “dressing”, “securement”, 
“polyurethane/transparent/occlusive”, “gauze”, “tape”, “failure”, “phlebitis”, “infection”, 
“occlusion”, “dislodgement/accidental removal/migration”, “infiltration”, “premature 
removal” and “complications”. There was no language or date restriction. We also searched 
reference lists of articles identified. We published a systematic review in 2015 (last search 08 
April 2015), of 6 trials with a total of 1539 participants. Of four product comparisons, only one 
contained data from more than one RCT, and the overall quality of evidence was very low. 
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Simple (non-bordered) Polyurethane dressings were associated with less dislodgement (Risk 
Ratio [RR] 0∙40, 95% CI 0∙17–0∙92; 2 trials, N=278) than Gauze with Tape, but the effect (3 
trials, N=379) on phlebitis (RR 0∙89, 95% CI 0∙47 to 1∙68), and infiltration (RR 0∙80, 95% CI 
0∙48 to 1∙33) was unclear. One study (N=703) reported an unclear effect of non-bordered 
Polyurethane on dislodgement (RR 1∙34, 95% CI 0∙72 to 2∙47) and phlebitis (RR 0∙89, 95% CI 
0∙53 to 1∙49), compared to Sticking Plaster. 
Individual trials reported Bordered Polyurethane to: (i) reduce dislodgement  (RR 0∙14, 95% 
0∙03 to 0∙63), but increase phlebitis (RR 8∙11, 95% CI 95% CI 1∙03 to 64∙02), compared to 
Securement Devices, with unclear effect on infiltration (RR 0∙79, 95% CI 0∙47 to 1∙33) or 
overall failure (RR 0∙86, 95% CI 0∙64 to 1∙16) (one study; N=302); (ii) and to have unclear 
effect on PIVC failure (RR 1∙84, 95% CI 1∙09 to 3∙11) and dislodgement (RR 1.46, 95% CI 
0∙51 to 4∙14) compared to Tape (one trial, N=153).  
Previous studies did not conclusively identify the optimal PIVC dressing and securement 
method. Some were limited to particular patient groups, outcome measures were often one type 
of complication, not overall PIVC failure, and costs were rarely considered. We concluded that 
a large trial was needed. 
Added value of this study 
We undertook a large randomised controlled trial in two hospitals. Patients with a PIVC were 
randomised to i) Tissue Adhesive with Polyurethane, (ii) Securement Device with 
Polyurethane, (iii) Bordered Polyurethane, or (iv) Polyurethane (controls). There was no 
significant difference in PIVC failure between groups. Total costs (dressing and securement 
products, staff time, response to PIVC failure and treatment of infections) were not 
significantly different between the four approaches; although if treatment cost for infection 
(uncommon but costly) were removed, Polyurethane was the least costly option. In all groups, 
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PIVC failure was common, and products had poor durability, often requiring reinforcement. 
Skin adverse events occurred in 2% of patients.   
Implications of all the available evidence 
Our trial suggests that choice of PIVC dressing or securement should be mainly based on cost, 
with no tested alternative clinically superior to low-cost Polyurethane. A previous trial (N=360) 
found significantly reduced PIVC failure using Tissue Adhesive with Bordered Polyurethane; 
we did not observe this effect when combining Tissue Adhesive with non-bordered 
Polyurethane. Our study highlights an unmet need to prevent PIVC failure through dressing 
and securement innovation.  
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INTRODUCTION  
Peripheral intravenous catheters (PIVCs) are the most common invasive medical device. 
Around two billion are sold globally each year, with almost all hospital patients requiring 
intravenous therapy.[1-3] PIVC failure is unacceptably common, with up to 69% removed for 
dislodgement, phlebitis, occlusion, infiltration or infection.[4-7] Such events cause pain and 
anxiety, interrupted therapy, infection-related morbidity and mortality, additional procedures 
for replacement catheters, and substantially increase healthcare costs and workloads. 
 
Effective dressing and securement should prevent many PIVC complications, avoiding gross 
dislodgement from the vein, but also micro-motion of the device within the vessel that 
precipitates venous inflammation, occlusion, and entry of skin site bacteria into the PIVC 
wound.[8, 9] Global clinical practice guidelines require PIVC dressings to be clean, dry and 
intact, with devices well secured.[10, 11] In contrast, 21%–71% of PIVC dressings are soiled, 
moist, loose, and/or inadequately secured at any timepoint.[1, 12] 
 
The traditional PIVC dressing is commercially-manufactured, sterile, adhesive, transparent 
polyurethane film, with sterile gauze alternatively used for ooze/diaphoresis. [10, 13] Non-sterile 
tape is commonly added to both approaches. There is growing realisation that polyurethane 
dressings provide inadequate securement.[10] More recently available products may improve 
securement through an additional reinforced tape/cloth border (Bordered Polyurethane), 
adhesive Securement Devices (applied in addition to the dressing), and cyanoacrylate adhesive 
added to the PIVC entry point/hub (under the dressing). These increase purchase cost and 
complexity but would be desirable if PIVC failure is prevented. 
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PIVC dressing and securement is a poorly-researched area of patient safety. A 2015 Cochrane 
review noted current evidence is low quality with no superior method identified.[14] We tested 
the efficacy, cost, and acceptability to patients and clinicians of traditional low-cost 
Polyurethane compared to three alternatives – Bordered Polyurethane, Securement Device with 
Polyurethane, and Tissue Adhesive with Polyurethane. We aimed to assist policy makers with 
decision making about the best PIVC dressing and securement choice.  
 
METHODS  
Study design and participants 
We undertook a randomised, controlled, pragmatic trial of parallel, superiority design at two 
hospitals in Queensland, Australia. Human research ethics committee approval was obtained 
from the health services (HREC/11/QRCH/152) and Griffith University (NRS/46/11/HREC) 
and the protocol was published.[15] We recruited adults from medical-surgical departments who 
had a PIVC of expected use >24 hours. Intensive care units (ICUs) were not included as PIVCs 
are rarely used in Australian ICUs. Only one PIVC was studied per patient (the first for each 
patient that met the inclusion criteria). Exclusions were: non-English speaking patients without 
interpreters; PIVCs inserted through damaged skin; severe diaphoresis; known study product 
allergies; terminal care; current or high risk of a skin tear (clinician opinion). A small team of 
Research Nurses (ReNs) screened for and explained the study to eligible patients, and requested 
written, informed consent from patients/representatives. 
 
Randomisation, allocation concealment and blinding 
Randomisation was computer-generated per participant using a centralised, web-based service 
(https://www151.griffith.edu.au/). We used randomly varied block sizes, stratification by 
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hospital, and a 1:1:1:1 ratio to: (i) Tissue Adhesive with Polyurethane, (ii) Bordered 
Polyurethane, (iii) Securement Device with Polyurethane, or (iv) Polyurethane (controls). 
Allocation was concealed until after patient consent, at which time the ReN contacted the 
randomisation service, advised the inserter of the allocation and documented this. Due to the 
nature of the intervention, clinical and research staff were not masked, however infection 
endpoints were adjudicated by a blinded rater. A Study Manager trained and supervised ReNs, 
audited data quality and randomisation compliance. Standard operating procedures and study 
manuals were in place. 
 
Study Products 
Study products are shown in Figure 1. The study products were chosen as globally market 
leading products typical of their category, and available in Australia. Control participants had 
an unbordered Polyurethane (Tegaderm™ Transparent Film Dressing 1624W/1626W, 3M, St 
Paul) to affix the PIVC. Product size was chosen by inserters to suit patient size and insertion 
site (approximately 60% were 6cm x 7cm [1624W] and 40% were 10 x 12 cm [1626W]). 
 
The Tissue Adhesive with Polyurethane group had 1–2 drops of cyanoacrylate (Histoacryl™ 
Blue, BBraun #1050044, Ann Arbor) applied to the PIVC insertion wound and 1–2 drops under 
the PIVC hub (and PIVC wings, if present). This dried in approximately 10 seconds while the 
PIVC was held in position, before the Polyurethane (as before) was applied. 
 
The Bordered Polyurethane group had a Tegaderm™ I.V Advanced Securement dressing 10 x 
7cm (Ref # 1683, 3M, St Paul) placed on the PIVC. This had a central polyurethane component, 
with a reinforced adhesive border on three sides. 
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The Securement Device with Polyurethane group had a StatLock® IV Select (Ref #IV0525, 
Bard Access Systems, Utah) (Site 1), or GripLok™ Medium Universal Securement with Wide 
Silicone Adhesive area (Ref #330MWA) (TIDI, Wisconsin) (Site 2), and Polyurethane (as 
before) applied to the PIVC. These were selected to suit the winged/non-winged PIVC used 
routinely at the site. Securement Devices were placed outside of (not under) the Polyurethane.  
 
One strip (approximately 12∙5 cm) of non-sterile tape (3M™ Micropore™ 25mm x 9∙1m, Ref 
# 1530–1) was standardly applied on the short extension set in all groups, except Securement 
Device with Polyurethane participants at Site 2 since this product itself secured the extension 
set. 
 
Procedures  
We chose a pragmatic design, so as to understand how the interventions worked under ‘real-
world’ conditions, this included the intra and inter-hospital heterogeneity typical of PIVC care. 
PIVCs were inserted by ward nurses and doctors or an experienced nurse inserter; ultrasound 
was not used. PIVC site, catheter gauge and attachments were chosen by the inserter in 
consideration of patients’ needs. Skin preparation was alcoholic chlorhexidine (CHG) 
(SoluPrep™ Swab 2% CHG in 70% isopropyl alcohol [IPA], Ref #102.03 [3M, St Paul] at Site 
1, and Persist™ Plus 1% CHG in 70% IPA [BD, Utah] at Site 2). PIVCs were Insyte™ 
Autoguard™ Blood Control (non-winged) (BD) at Site 1, and Introcan Safety®3 (winged) (B 
Braun) at Site 2. Smart-Site™ Needle-Free Valve (Ref # 2000E, BD) (Site 1) or MaxPlus™ 
Clear Needle-Free Valve (Ref #MP1000C–0006, BD) (Site 2) were connected to PIVCs 
directly or via an extension set. Site 1 used 10cm extension sets with bonded 3-way Connecta™ 
(Ref #394995, BD) and Smart-Site™, or for Securement Device participants, a 15cm luer lock 
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extension with Smart-Site™ was included. Site 2 used 15 cm extension sets with bonded 
Smart-Site™ (Ref#10010511).  
 
All post-insertion care was by clinical, not research staff, or IV teams. Bedside nurses decided 
if replacement/reinforcement of study products was required during PIVC dwell (i.e. when 
products became loose, moist or soiled). ReNs recorded product replacements or modifications 
and advised staff about study products prior to study commencement and during the trial. The 
decision to remove PIVCs was that of the clinical (not research) staff. The Site 1 policy for 
PIVC removal was initially only for therapy completion or complications; this changed mid-
trial to a 72–96 hour removal policy. Site 2 had a routine 72–96 hour removal policy throughout 
with stricter enforcement. In both sites, dwell time could be extended >96 hours if the PIVC 
was still needed, had no signs or symptoms of catheter dysfunction or infection, and there was 
a clinical justification (e.g. patient had poor veins).  
 
ReNs visited participants daily while the PIVC was in situ, or until skin adverse events 
resolved. Baseline patient and PIVC characteristics were recorded. During dwell, data were 
collected on PIVC therapy, dressing and securement type and condition, and insertion site 
condition (redness, pain, tenderness, swelling, purulence, palpable cord or vein streak). At 
PIVC removal, ReNs recorded complications present, dwell time, current clinical variables, 
and verbal patient (if able) overall satisfaction with the study products (0=completely 
dissatisfied, 10=completely satisfied). ReNs also asked the nurse who removed the products to 
verbally rate the difficulty of removal (0=very difficult, 10=very easy). At 48 hours post PIVC 
removal, ReNs checked the hospital pathology system for blood, PIVC tip or insertion site 
culture results. 
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All data were entered into password-protected, portable electronic device with REDCap 
(Research Electronic Data CAPture, http://project-redcap.org/) database and form-based 
interface. Clinical staff did not have access to this data and continued routine practices for 
PIVC monitoring. A Project Manager audited data quality, completeness and protocol 
adherence with at least monthly site visits for training and monitoring.  
 
As per usual practice, clinical staff ordered blood, PIVC tip or site swab cultures if patients 
were suspected of PIVC associated infection. These were obtained by bedside nurses, 
processed in the hospital pathology laboratory by blinded staff, with results accessed by 
researchers. To further determine infection risk associated with the study products, a sub-study 
of PIVC tip and insertion site skin cultures was undertaken by the researchers using a blinded 
microbiologist. [12, 16] For this, convenience sampling was used when ReNs were available at 
the time of PIVC removal to take specimens, which were then cultured within 24 hours.  
 
Outcomes 
The primary outcome was all-cause PIVC failure. This was a composite measure of 
complications at PIVC removal: dislodgement (Partial dislodgement: PIVC retracted so that 
tip is no longer in the vein but remains under the skin +/- IV fluids leaking from insertion site. 
Complete dislodgement: entire PIVC dislodged from patient’s body), occlusion (includes 
infiltration and extravasation), phlebitis (one or more signs/symptoms), or infection (primary 
bloodstream [BSI], or laboratory confirmed local PIVC infection).[13, 17] All-cause PIVC failure 
is often used in PIVC trials since the common outcome is a non-functional device. Outcome 
data were collected by ReNs by patient examination, from hospital and pathology records, or 
reports from bedside nurses, doctors or competent patients. Infection outcomes were blind-
rated by an infectious diseases physician.  
11 
 
 
Secondary outcomes included sub-types of PIVC failure (as above), PIVC dwell, and study 
product dwell (durable hours from application). Secondary endpoints from the substudy were 
PIVC and skin colonisation (>15 colony forming units [CFU]).[16] Patient satisfaction (overall 
with product) and staff satisfaction (with removal) were verbally ranked on a 11-point ordinal 
scale. 
 
ReNs assessed daily for adverse events potentially associated with the study products including 
rash, blister, itchiness, as well as adhesive residue or skin tears on product removal. Serious 
adverse events (death, admission to intensive care, and/or primary BSIs) were monitored from 
hospital records and reported to the Human Research Ethics Committee. A Data Safety 
Monitoring Committee was not formed due to the rapid recruitment. 
 
Total resource use and costs were calculated for each group. This included products applied at 
PIVC insertion and staff time to apply these, plus products used for replacement or 
reinforcement, additional PIVC insertions (if the device failed and was replaced), and costs of 
treating local or primary BSIs (appendix table 1). Purchase costs were 2016 Queensland Health 
prices (Australian dollars [AU$]). The time taken to apply study products was recorded for 127 
insertions selected at random (minimum 26 per group). Nursing and medical staff time was 
based on published staff salaries, updated to 2016.[18] Costs for treatment of local PIVC 
infections or primary BSIs used the National Efficient Price Determination (2015–16), and for 
other complications/adverse events by cost of a replacement PIVC and/or dressing.[5, 19] If a 
primary BSI infection and a local PIVC infection co-occurred, only the cost of the primary BSI 
was attributed. 
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Statistical analysis 
The pre-study prevalence of PIVC failure at the study sites using Polyurethane was 40%.[5] We 
hypothesised that each of the three alternatives would reduce failure by an absolute 10%, i.e. 
to 30%. This difference was considered clinically important.[20, 21] Sample sizes were calculated 
for three superiority tests of two proportions with 90% power at p=0∙05. Alpha adjustment was 
not undertaken consistent with our study design of separate hypothesis testing of the effect of 
multiple alternative treatments (that did not inform a single claim of effectiveness) on one 
primary endpoint, with a shared control group.[22] This resulted in each group requiring 388 
participants, plus 10% for potential attrition (1708 in total). 
 
Data cleaning involved checks of missing, outlier and improbable values with source data 
verification and corrections for ~10% of patients. Categorical data were summarised as counts 
and proportions, and continuous/ordinal data as means (standard deviation) or median 
(interquartile limits), if not normally distributed. Comparability of groups at baseline for risk 
of device failure was by clinical criteria.  Missing data for primary and secondary endpoint 
variables were not imputed. 
 
In the primary analysis, all randomised patients with the primary endpoint available were 
analysed by intention to treat (ITT), with the patient as the unit of measurement. Relative 
incidence rates of PIVC failure per 100 devices and per 100 device days with incident rate 
ratios and 95% confidence intervals were used to summarise the effectiveness of each 
intervention, and to test for group differences. Kaplan-Meier survival curves (with log rank 
Mantel-Cox test) compared failure over time. Multivariate Cox regression was used to calculate 
hazard ratios for PIVC failure, adjusted for treatment group, for variables associated with PIVC 
failure at p<0∙2 on bivariate regression, and for study site because of significantly different 
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average PIVC dwell times, i.e. different duration of exposure to risk. Variances in effect sizes 
between study sites were assessed and although absolute failure incidence differed, this was 
not different per 100 hours.  
 
Secondary endpoints were compared between groups using parametric or nonparametric 
techniques as appropriate to level of measurement. A per protocol analysis included patients 
who had one of the four study treatments for at least 24 hours from PIVC insertion, with 
censoring if the treatment was modified (i.e. additional products added later). A cost analysis 
was undertaken from the perspective of public hospitals, as they are the main purchasers of 
PIVC dressings and securements. Mean costs (including costs of responding to all adverse 
events) for the three treatment groups were compared with Polyurethane controls using non-
parametric bootstrapping. P values <0∙05 were considered significant. The trial was registered 
with the Australian New Zealand Clinical Trials Registry (ACTRN 12611000769987).  
 
RESULTS   
Sample 
Between March 18, 2013, and September 9, 2014, we screened 2382 patients and randomly 
allocated 1807 participants to Tissue Adhesive with Polyurethane (446), Bordered 
Polyurethane (454), Securement Device with Polyurethane (453) or Polyurethane (454) (Figure 
2). In total, 98/1807 (5∙4%) randomised patients had a failed or cancelled PIVC insertion so 
the study products were never applied and no data were collected on these patients (Fig 2). No 
patients withdrew consent. The primary endpoint was unable to be determined in full (with the 
exception of infection outcomes) for 12 participants (4 each in Tissue Adhesive with 
Polyurethane and Bordered Polyurethane groups; 2 each in Securement Device with 
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Polyurethane and Polyurethane groups), thus 1697 of the 1709 (99%) who had a PIVC inserted 
were included in the ITT analysis. There were 115,408 PIVC hours/4,809 PIVC days studied, 
with the proportion of PIVCs removed by day of dwell being: Day 1 (16%), 2 (26%), 3 (20%), 
4 (16%), 5 (9%), 6 (5%), 7 (3%), 8 (2%), 9 (1%), 10 (1%) or 11–18 (1%). Clinical and 
demographic characteristics were similar between groups for both patients and PIVCs (table 
1).  
 
For the primary outcome of PIVC failure, absolute risk differences between groups were less 
than the predefined 10% margin, therefore we rejected the superiority hypotheses. PIVC failure 
was experienced by 38% (Tissue Adhesive with Polyurethane, 13∙3/100 days), 40% (Bordered 
Polyurethane 14∙6/100 days), 41% (Securement Device with Polyurethane, 14∙2/100 days) and 
43% (Polyurethane, 15∙1/100 days) of participants (table 2). PIVC failure was not significantly 
different between any of the three intervention groups and controls for per patient (p=0∙21 to 
0∙74, table 2), per 100 PIVC days (p=0∙25 to 0∙82, table 2), or survival (p=0∙57, figure 3) 
analyses. Sensitivity analyses of group differences by site did not indicate confounding by use 
of different PIVC and Securement Device brands at the two study sites (all p>0∙05). 
 
Most (1685 of 1709, 98∙6%) participants with a PIVC received the allocated intervention 
(figure 2). Of the remaining 24 participants, 17 received an incorrect study group allocation, 
and 7 received non-study products. Additional dressings and/or securements were added for 
1130 (66%) participants on some/all dwell days (N=585 within 24 hours of PIVC insertion). 
This involved 71% of Tissue Adhesive with Polyurethane, 61% of Bordered Polyurethane, 
56% of Securement Device with Polyurethane, and 77% of Polyurethane participants. In the 
per protocol analysis (n=1100), 17 patients changed groups and we included 746 participants 
who received no treatment modification and 354 participants who received at least the initial 
15 
 
24 hours of allocated treatment (with censoring if alterations occurred later). In this analysis, 
Tissue Adhesive with Polyurethane, but not Bordered Polyurethane or Securement Device with 
Polyurethane, was associated with significantly less PIVC failure compared to Polyurethane 
controls (table 2).  
 
Regarding secondary outcomes, occlusion was significantly less frequent for Tissue Adhesive 
with Polyurethane than Polyurethane controls (5.6 vs 7.9 per 100 days, p=0∙027, table 2), but 
did not significantly differ for Bordered Polyurethane or Securement Device with 
Polyurethane, compared to Polyurethane. Dislodgement and phlebitis incidences were not 
statistically different between any of the intervention groups, and Polyurethane controls.  
 
Three patients developed a primary BSI, two in the Bordered Polyurethane group (one patient 
with Pseudomonas aeruginosa; one patient with Enterobacter cloacae [E. cloacae] and 
Citrobacter braakii), and one in the Polyurethane group (E. cloacae) (table 2). Of these, one 
was confirmed as catheter-related (CRBSI) via a matching positive tip culture (Polyurethane 
group; E. cloacae). There was one laboratory confirmed local site infection which occurred in 
the Polyurethane group (E. cloacae – this event was also the CRBSI described above).  
 
The median PIVC dwell time was 54 hours (interquartile range [IQR] 29, 94). This did not 
differ significantly between any of the three intervention groups and the Polyurethane group 
(table 2). The average dwell time differed between Site 1 (72∙7 hours) and Site 2 (58∙2 hours). 
Although commonly reinforced, the initial study products were rarely replaced, remaining on 
average for 52 hours (IQR 28, 92; not significantly different between any intervention group 
and controls).  
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The microbiological sub study found positive tip cultures in 0–4% per group, which was not 
significantly different between intervention and control groups (table 2). Skin cultures were 
positive (any growth) in 10% to 19% per group (not significantly different between intervention 
and control groups). 
 
The initial mean (95% CI) costs were substantially higher per patient for products and staff 
time for all three experimental groups compared to the control group (table 3). When the costs 
of replacement for failed PIVC devices and replacement/reinforcement of study products were 
added, costs were significantly (p<0.001) higher per patient for all three experimental groups 
compared to the control group (difference in means AU$15.53 [15.27-15.78], AU$3.86 [3.78-
3.94], AU $7.51 [7.41-7.61] for Tissue Adhesive with Polyurethane, Bordered Polyurethane, 
and Securement Device with Polyurethane respectively compared to Polyurethane). However, 
overall mean costs per patient were not significantly different between any experimental group 
and the control group, once treatment costs for the three primary BSIs were included. 
 
There were 39 skin injury adverse events associated with study products (14 rash, 12 pruritus, 
8 skin tear, 4 blister, and 1 pressure area) in 34 patients, occurring in all groups. Only Tissue 
Adhesive with Polyurethane was significantly different to controls (4.0% vs 1.7%, p=0∙04, 
table 2). Serious adverse events (death, ICU admission or primary BSI) occurred in 15 (0∙9%) 
patients overall. Deaths and ICU admissions were not related to study participation. 
 
Patients and bedside nurse satisfaction scores were generally satisfied with all products tested 
(table 2). Tissue Adhesive with Polyurethane received a significantly higher rating from 
patients, but a significantly lower rating from nurses, compared to Polyurethane, however these 
differences were <1 point on an 11-point scale.  
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DISCUSSION  
This large pragmatic randomised controlled trial of PIVC dressing and securements found 
PIVC all-cause failure to be highly prevalent, at 41% overall. We tested three alternatives 
against a traditional low-cost Polyurethane control dressing, but none significantly reduced 
PIVC failure. Overall, there was no significant difference in costs between dressing and 
securement alternatives, although this included infection treatments, which were high cost but 
uncommon and not different between groups. Excluding infection treatment costs, the total 
mean costs per patient of Polyurethane were significantly less than those of any of the three 
alternatives and represented savings of up to AU$15.53 (95%CI 15.27-15.78) per patient. All 
products tested, including Polyurethane, were commonly associated with PIVC failure, and 
often needed reinforcement – innovation to achieve effective, durable products is urgently 
needed.   
 
This study indicates potential substantial savings to the health system if clinicians ‘choose 
wisely’ and opt for low cost Polyurethane for PIVCs, in the absence of clinical rationale for 
use of a more expensive product.[23, 24] A recent cross-sectional study in 51 countries reported 
56% of PIVCs as secured with Polyurethane, 22% with Bordered Polyurethane, 5% with 
Securement Devices, and Tissue Adhesive use unknown but growing.[1, 25] With two billion 
PIVCs used globally each year, disinvestment of AU$3.86 to AU$15.53 per PIVC so that 100% 
are secured with Polyurethane could save AU$3.4 to AU$13.7 billion per year in products, 
staff time and responses to PIVC failure (excluding infections).[3]  
 
Bordered Polyurethane dressings were developed to improve securement over traditional 
Polyurethane dressings, but we found these to have no less complications and failure, 
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confirming results of smaller studies.[26, 27] Further, the durability of both Polyurethane and 
Bordered Polyurethane (one of which was used in all four study groups) was poor, with 
reinforcement frequently required, commonly due to lost adherence at one or more parts of the 
dressing. This occurred in over half of our patients, indicating poor performance during typical 
clinical conditions, even with a short (average 2∙4 days) PIVC dwell. Securement Devices with 
Polyurethane had non-statistically lower PIVC failure compared to Polyurethane dressings in 
one previous small randomised trial, but no benefit was seen in our study.[26]  
 
Our secondary outcomes included significantly reduced occlusions in the Tissue Adhesive with 
Polyurethane group, although the 6% absolute reduction was less than the significant 10% 
reduction in failure observed in a smaller study which followed patients for a shorter, 48 hour 
maximum PIVC dwell.[25] Tissue Adhesive is applied directly at the PIVC skin entry point and 
under the PIVC hub (+/- wings), possibly reducing micro-motion and internal vein damage.[26] 
Our per protocol analysis further suggested Tissue Adhesive’s potential benefit, but many 
patients required additional dressing reinforcement, and its use in combination with 
Polyurethane alone is unlikely to benefit the hospital population at large. If more durable 
dressings are identified, Tissue Adhesive may be a useful adjunct in the future. The low BSI 
incidence precludes definitive conclusions about comparative infection risk between study 
products, however we noted no infections associated with Tissue Adhesive, which has 
antimicrobial properties[28], nor in the Securement Device group, a product which may 
discourage skin microorganism entry into the wound via PIVC micro-motion.  
 
A recent, large, prospective cohort study supports the need for extra securement to reduce high 
PIVC failure, and the shortcomings of current approaches.[29]  Any additional securement (e.g. 
tape, elasticised tube, additional dressing) added to a Bordered Polyurethane was associated 
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with significant large reductions (HR 0∙3–0∙6) in occlusion, phlebitis and dislodgement.[29] 
These associations suggest multi-product combinations i.e. ‘securement bundles’ may be more 
effective for prevention of PIVC failure, than any one product alone, and should be tested in 
randomised studies. 
 
To our knowledge, no previous study has systematically tracked skin related adverse events 
associated with PIVCs. We observed one or more such complications in 2% of all patients. 
Rashes were most commonly, possibly reflecting irritation from the adhesive, or incorrect 
application of the dressing to skin still moist from pre-insertion antiseptics. Bruising was 
evident at 4% of PIVCs insertion sites, likely reflecting traumatic insertion, since 
ultrasound/other vein identification technologies were not used. 
 
Strengths of this study were its rigorous randomisation, daily follow up and prospective data 
collection processes. Generalisability of results was maximised by the heterogeneous nature of 
patients and PIVCs studied, with participants commonly at high risk due to age, obesity and 
multiple comorbidities. We avoided interfering with usual post-insertion care of PIVCs by 
bedside staff so as to understand real world effectiveness. Although 5% of randomised patients 
did not go on to receive a PIVC and were therefore excluded, this could not have been impacted 
upon by the choice of dressing and securement product. For those patients with a PIVC, 99% 
received the allocated intervention and 99% were included in the primary analysis.  
 
The bottom-up, micro-costing approach including detailed costing for staff time associated 
with study products is also a strength. Although the protocol specified a cost-effectiveness 
analysis to estimate incremental cost per PIVC failure avoided[15], we considered this of little 
value since no group had superior primary outcomes. Instead, our economic analysis is 
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pragmatic and incorporates costs of the interventions and those of managing complications and 
adverse events. In keeping with the hospital perspective, post discharge costs were not studied 
which is a potential limitation. However the complication most plausible to have post discharge 
costs (primary BSIs) had treatment costs included up until hospital discharge, by which time 
all six cases had resolved, thus our approach was unlikely to have altered study conclusions. 
 
Study limitations included the majority of PIVC insertions by RN expert inserters which may 
have reduced the risk of PIVC failure. However the incidence of 41% PIVC failure is consistent 
with our previous studies using less experienced inserters, thus poor securement may outweigh 
benefits of optimal insertion.[5, 29] The products used were unable to be blinded, and we did not 
formally assess inter-rater reliability, but risk of bias was reduced by outcome assessment using 
a small number of trained observers using clear definitions, blinded infection outcome 
assessors (100% agreement), all supervised and audited by a study manager. We have 
previously established 98% agreement (Cohen’s kappa 0.33) for phlebitis measures in our 
group.[8] The study sites used different PIVC and securement devices, but there was no 
significant confounding in effect sizes by site, suggesting that this did not introduce bias. We 
tested various product ‘categories’ (e.g. Bordered Polyurethane), but results may not reflect all 
product types within these categories, or be generalizable to other patient groups such as 
paediatrics. Our sample size was adequate to test our a priori hypotheses of 10% absolute 
reduction in the primary endpoint for all three intervention groups, but observed reductions 
were 2% to 5%. To confirm the largest observed difference in PIVC failure (Tissue Adhesive 
with Polyurethane 38%; Polyurethane 43%) would require a study of approximately 3000 
patients (p=0∙05, 80% power). We acknowledge some published views differ, but we did not 
undertake alpha adjustment as our study design tested separate hypotheses of three alternative 
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treatments (not varying doses of the same treatment) for one primary endpoint against a shared 
control group.[22, 30, 31] 
 
Both the Centers for Disease Control Guidelines and the Infusion Therapy Standards of 
Practice consider optimal PIVC dressing and securement to be unresolved.[10, 13] Both 
documents reflect the conclusions of a 2015 systematic review and meta-analysis which 
highlighted the paucity of high quality randomised studies. Regulatory bodies currently do not 
require evidence of effectiveness for device (e.g. dressing) registration (unlike 
pharmaceuticals), and manufacturers and independent funders rarely support randomised trials 
for efficacy or cost-effectiveness. With extensive global use of PIVCs, highly prevalent PIVC 
failure, and substantial costs to healthcare providers for dressing and securement products, 
further investment and innovation for effective products are urgently needed. 
 
CONCLUSION  
Almost all hospitalised patients worldwide receive one or more PIVCs, of which up to half are 
removed due to complications, causing substantial waste, discomfort, cost and harm. Better 
dressing and securement would likely prevent many complications but the optimal method 
remains elusive. Until a superior method is identified, cost should be the major factor to 
consider in choice of products. 
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Tissue adhesive with 
Polyurethane group 
(n=431) 
Bordered Polyurethane  
group (n=427) 
Securement Device with 
Polyurethane group 
(n=427) 
Polyurethane control group 
(n=424) 
Days studied (n) 1228 1154 1239 1188 
Age (median, IQR) 59 (45, 71) 61 (44, 72) 61 (44, 74) 61 (48, 72) 
Male  256 (59%) 241 (56%) 237 (56%) 253 (60%) 
Female 175 (41%) 186 (44%) 190 (44%) 171 (40%) 
   Medical 209 (48%) 217 (51%) 220 (52%) 222 (52%) 
   Surgical 194 (45%) 187 (44%) 182 (43%) 186 (44%) 
   Oncology 28 (6%) 23 (5%) 25 (6%) 16 (4%) 
Three or more co-morbidities        196 (45%) 195 (46%) 201 (47%) 213 (50%) 
   Obese 61 (14%) 54 (13%) 60 (14%) 59 (14%) 
   Overweight 123 (29%) 123 (29%) 121 (29%) 131 (31%) 
   Healthy weight 192 (45%) 207 (48%) 209 (49%) 180 (43%) 
   Emaciated 55 (13%) 43 (10%) 34 (8%) 53 (13%) 
Leucocytes <1000 / μl abs. 1 (0.2%) 0 (0%) 2 (0.5%) 2 (0.5%) 
Any infection at recruitment 77 (18%) 86 (20%) 84 (20%) 85 (20%) 
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Wound (pre-existing) 183 (42%) 184 (43%) 170 (40%) 176 (42%) 
Stoma 23 (5%) 37 (9%) 21 (5%) 23 (5%) 
Tracheostomy 7 (2%) 11 (3%) 11 (3%) 10 (2%) 
“Good” skin integrity 171 (40%) 180 (42%) 169 (40%) 164 (39%) 
Skin type: Fitzpatrick scale     
Pale white  60 (14%) 65 (15%) 70 (17%) 67 (16%) 
   White 269 (63%) 265 (62%) 263 (62%) 263 (62%) 
   Light Brown 70 (16%) 74 (17%) 65 (15%) 87 (16%) 
   Moderate Brown/Dark brown/Deeply 
pigmented dark 
31 (7%) 22 (6%) 26 (7%) 27 (6%) 
IV antibiotics during dwell 257 (60%) 249 (58%) 265 (62%) 270 (64%) 
Regular flush (documented) 13 (3%) 12 (3%) 14 (3%) 13 (3%) 
Dominant side insertion 235 (57%) 214 (53%) 228 (55%) 220 (53%) 
   IV expert nurse  369 (86%) 373 (87%) 379 (89%) 377 (89%) 
   Bedside  nurse 38 (9%) 31(7%) 27 (6%) 28 (7%) 
   Medical officer 22 (5%) 22 (5%) 19 (4%) 19 (4%) 
   Anterior upper forearm 130 (31%) 132 (31%) 106 (25%) 128 (30%) 
   Posterior lower forearm 123 (29%) 125 (29%) 107 (25%) 107 (25%) 
   Wrist 52 (12%) 65 (15%) 69 (16%) 67 (16%) 
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   Posterior upper forearm 41 (10%) 25 (6%) 32 (8%) 30 (7%) 
   Hand 27 (6%) 31 (7%) 32 (7%) 25 (6%) 
   Cubital fossa 20 (5%) 22 (5%) 27 (6%) 17 (4%) 
   Anterior lower forearm 17 (4%) 19 (4%) 21 (5%) 21 (5%) 
   Anterior upper arm 18 (4%) 7 (2%) 26 (6%) 24 (6%) 
   Posterior upper arm 5 (1%) 1 (0%) 7 (2%) 3 (1%) 
Insertion attempts: single 346 (80%) 350 (82%) 337 (79%) 331 (78%) 
Bruised insertion site 17 (3∙9%) 10 (2∙3%) 18 (4∙2%) 23 (5∙4%) 
Skin prep CHG in alcohol* 422 (98%) 421 (99%) 424 (99%) 419 (99%) 
  22G 303 (71%) 300 (71%) 303 (71%) 311 (73%) 
  20G 118 (28%) 116 (27%) 117 (28%) 104 (25%) 
  18G 5 (1%) 5 (1%) 2 (1%) 5 (1%) 
10–15cm extension tubing 156 (36%) 149 (35%) 425 (100%)¶ 145 (34%) 
3 way connector  268 (63%) 274 (64%) 10 (2%) 276 (65%) 
Multiple pieces of non-sterile tape on 
device ≥1 dwell days 107 (25%) 83 (19%) 80 (19%) 123 (29%) 
Infusion tubing (if used) is secured on 
all days§ 69 (19%) 80 (25%)  72 (21%) 78 (23%) 
Hair unclipped at PIVC site 192 (45%) 184 (43%) 191 (45%) 182 (43%) 
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Data are median (IQR) or n (%). *Skin prep 70% alcohol swab (N=5), skin prep missing (n=18); ¶Securement Device required an extension tubing to apply; §n=1363 had one 
or more days with infusion tubing 
Table 1: Baseline, demographic and clinical characteristics of 1709 randomised patients who received a PIV 
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 Tissue adhesive with 
Polyurethane group 
(n=427) 
Bordered Polyurethane 
group (n=423) 
Securement Device with 
Polyurethane group 
(n=425) 
Polyurethane 
control group (n=422) 
Overall 
(n=1697) 
Primary Endpoint, ITT 
   PIVC failure/patient, p-value~ 163 (38%), p=0∙21 169 (40%), p=0∙46 176 (41%), p=0∙74 180 (43%) 688 (41%) 
PIVC failure/100 PIVC days (95% 
CI) 
13∙3 (11∙2–15∙3) 14∙6 (12∙4–16∙8) 14∙2 (12∙1–16∙3) 15∙1 (12∙9–17∙4)  
Relative risk (95% CI), p-   value*) HR 0∙96 (0∙89–1∙03), 
p=0∙25 
HR 0∙98 (0∙79–1∙20), 
p=0∙82 
HR 0∙96 (0∙87–1∙07), 
p=0∙47 
-  
Per protocol  
PIVC failure/patient, failure/100 
days 
74/281 (26%), 12∙7 96/273 (35%), 19∙6 100/296 (34%), 15∙9 86/250 (34%), 18∙3  
Relative risk (95%CI), p-value*) HR 0∙88 (0∙79– 0∙98), 
p=0∙018 
HR 1∙10 (0∙82–1∙48), 
p=0∙52 
HR 0∙91 (0∙79–1∙05), 
p=0∙20 
  
Secondary outcomes 
Occlusion, n/100 days (HR, 95% 
CI, p-value*) 
69 (16%), 5∙6 (HR 
0∙89, 0∙80–0∙99, 
p=0∙027) 
82 (19%), 7∙1 (HR 0∙91, 
0∙68–1∙22), p=0∙54) 
98 (23%), 7∙9 (HR 1∙00, 
0∙87–1∙15), p=0∙99 
94 (22%), 7∙9 343 (20%) 
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Phlebitis ( ≥1 sign/symptom), 
n/100 days (HR, 95% CI, p-value*) 
108 (25%), 8∙8 (0∙98, 
0∙90–1∙07, p=0∙66) 
94 (22%), 8∙2 (0∙87, 
0∙66–1∙15, p=0∙33) 
109 (26%), 8∙8 (0∙95, 
0∙83–1∙08, p=0∙42) 
112 (27%), 9∙4 423 (25%) 
Dislodgement, n/100 days (HR, 
95%CI, p value*) 
29 (7%), 2∙4 (0∙86, 
0∙74–1∙01, p=0∙07) 
40 (9%), 3∙5 (0∙97, 0∙63–
1∙50, p=0∙89) 
37 (9%), 3∙0 (0∙94, 0∙75–
1∙17, p=0∙55) 
42 (10%), 3∙5 148 (9%) 
Primary bloodstream infection  0 2 (0∙47%) 0 1# (0∙24%) 
 
3 
Local PIVC infection 0 0 0 1§ (0∙24%) 1 
PIVC dwell time, median h, (IQR) 56 (29, 95) 50 (28, 92) 55 (28, 94) 55 (30, 92) 54 (29, 94) 
1st study product dwell time,   median 
h, (IQR)¥, Ω 
55 (28,95) 50 (28,91) 52 (26,90) 52 (29,89) 52 (28,92) 
Substudy (n=137) 
Tip colonised >15cfu¥ 2/48 (4%) 1/52 (2%) 0/59 (-) 1/56 (2%) 4/215 (2%) 
Skin colonised >0cfu¥ 9/48 (19%) 10/52 (19%) 6/59 (10%) 7/56 (13%) 32/215 (15%) 
Skin adverse events 17 (4∙0%)Ψ 2 (0∙5%)¥ 8 (1∙9%)¥ 7 (1∙7%) 34 (2∙0%) 
Serious adverse events¥ 4 (0∙9%) 4 (0∙9%) 4 (0∙9%) 3 (0∙7%) 15 (0∙9%) 
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Patient overall satisfactionɸ (0-10 
scale) mean, median (IQR), p-value˄ 
N=363 
8∙6, 9 (8,10) 
p<0∙001 
N=368 
8∙3, 9 (8,10) 
p<0∙001 
N=360 
7∙9, 8 (7, 10)  
p=0∙15 
N=380 
7∙7, 8 (7, 10)  
referent 
N=1,471 
8∙1, 0 (8, 10) 
Nurse satisfaction with removal (0-10 
scale) mean, median (IQR), p-value˄ 
N=324 
8∙2, 9 (8,10) 
p<0∙001 
N=338 
8∙8, 9 (8,10) 
p=0∙99 
N=333 
8∙2, 9 (7,10) 
p<0∙001 
N=343 
8∙7, 9 (9,10) 
referent 
N=1338 
8∙5, 9 (8, 10) 
Data are n (%). Patients with missing primary endpoint data (n=12) not included in this analysis. HR=Hazard ratio. H=hours. IQR= inter-quartile range (25th and 75th 
percentiles). ~Fisher exact test of independence (2-sided). *Cox regression. #PIV-related bloodstream infection (matched colonised tip and exudate). §associated with a BSI 
(matched organism). Ψp=0.04. ¥p>0∙05 for each study group against control; Ω98/1687 had initial products replaced. ɸ13∙5% missing data. ˄Wilcoxon rank-sum test. 
Table 2: Study outcomes by treatment group (per patient analysis, MV logistic and Cox regression models, adjusted for study site) 
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 Mean costs per patient, AU$ (95% CI) 
Tissue Adhesive with 
Polyurethane group 
Bordered Polyurethane 
group 
Securement Device with 
Polyurethane group 
Polyurethane control 
group 
Overall 
N 427 423 425 422 1,697 
Initial dressing and 
securement products 
$12∙85 
(12∙64–13∙05) 
$3∙31 
(3∙26–3∙36) 
$5∙39 
(5∙32–5∙46) 
$0∙48 
(0∙45–0∙51) 
$5∙53 
Staff time costs to apply 
products  
$0.81 $0.72 $1.21 $0.60 $0.84 
Costs associated with initial 
PIVC  
$13∙66 
(13∙45–13∙86) 
$4∙01 
(3∙96–4∙07) 
$6∙62 
(6∙55–6∙70) 
$1∙08 
(1∙05–1∙11) 
$6∙37 
Replacement PIVCa, dressing 
and securement products, and 
staff time 
$4∙12 
(4∙07–4∙17) 
$2∙10  
(2∙08–2∙11) 
$3∙14  
(3∙12–3∙15) 
$1∙17  
(1∙16–1∙18) 
$2∙64 
Costs associated with initial 
and replacement PIVC 
$17∙78 
(17∙52–18∙03) 
$6.11 
(6.04, 6.18) 
$9∙76 
(9∙67–9∙85) 
$2.25 
(2.21, 2.29) 
$9.00 
Difference in means compared 
to polyurethane control 
 
$15.53 
(15.27 – 15.78) 
$3.86 
(3.78 – 3.94) 
$7.51 
(7.41 – 7.61) 
Referent  
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p-value c < 0.001 < 0.001 < 0.001 
Treatment of primary 
bloodstream infectionsb 
$0 $29.41 $0 $14.98 $11.06 
Total costs  $17∙78 
(17∙52–18∙03) 
$35.52 
(-5.57, 76.61) 
$9∙76 
(9∙67–9∙85) 
$17∙23 
(-12∙16–46∙63) 
$20.06 
Difference in means compared 
to polyurethane control 
 
p-value c 
$0∙55 
(-28∙92 – 30∙01) 
0.972 
$18.29 
(-32.63 – 69.20) 
0.457 
-$7∙47 
(-36∙94 – 21∙99) 
0.620 
Referent - 
Table 3. Costs associated with PIVC dressings by treatment group (ITT analysis) 
AU$ = Australian dollars; CI = confidence interval; PIVC = peripheral intravenous catheter. a Replacement PIVCs required in 22∙7% of Tissue Adhesive with Polyurethane; 
27∙9% of Bordered Polyurethane; 26∙6% of Securement Device with Polyurethane; and 26∙1% of Polyurethane control group patients; b two primary bloodstream infections 
in Bordered Polyurethane and one in Polyurethane controls; c non-parametric bootstrapping. 
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 Product Cost per unit AU$ Assumptions/ 
percentage of patients 
Polyurethane dressing Tegaderm™ Transparent 
Film dressing – 1624W 
(6 cm x 7 cm) (3M) 
$0∙2437 85% of Site 1 patients 
15% of Site 2 patients 
Tegaderm™ Transparent 
Film dressing – 1626W 
(10 cm x 12 cm) (3M) 
$0∙56 15% of Site 1 patients 
85% of Site 2 patients 
Bordered Polyurethane 
dressing 
Tegaderm™ IV 
Advanced Securement 
dressing – 1683 (10 cm x 
7 cm) (3M) 
$3∙264 100% of patients 
Securement Device StatLock® IV Select – 
IV0525 (Bard) 
$5∙254 100% of Site 1 patients 
GripLok™ Medium 
Universal Securement 
with Wide Silicone 
Adhesive area – 
330MWA (TIDI) 
$3∙75 100% of Site 2 patients 
Tissue Adhesive Histoacryl™ Blue – 
1050044 (Aesculap) 
$11∙80 100% of patients 
Uni-solve® wipes (Smith 
& Nephew) 
$0∙1696 2 per removal 
PIVC costs Insyte™ Autoguard™ 
Blood Control (non-
winged) (BD) 
$1∙99 100% of Site 1 patients 
Introcan Safety® 3 
(winged) (B Braun) 
$1∙47 100% of Site 2 patients 
Additional product costs Micropore™ non-sterile 
tape – 1530-1 (25 mm x 
9∙1 m) (3M) 
$0∙006  Per 12∙5 cm strip 
Sterile gauze $0∙034 Per use 
Tubifast® – medium 
(Molnlycke)  
$0∙1238 Per 12∙5 cm length; 
50% 
Tubifast® – large 
(Molnlycke) 
$0∙1365 Per 12∙5 cm length; 
50% 
Sterile tape $0∙798 Per use 
Local infection (J64B) $3,739∙60 Per patient affected 
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Infection treatment 
costs[19] 
Primary bloodstream 
infection (T60C) 
$6,351∙94 Per patient affected 
Staff costs updated to 
2016 costs[18] 
Registered nurse $0∙6228 Per minute 
Junior medical staff $0∙8692 Per minute 
Senior medical staff $1∙2702 Per minute 
Appendix Table 1. Costs associated with each study group: initial, additional and replacement products 
and staff time, and costs of responding to PIVC failure 
AU$ = Australian dollars; PIVC = peripheral intravenous catheter 
 
 
 
 
 
